×

Error message

  • Failed to authorize with Brightcove
  • Failed to authorize with Brightcove
  • Failed to authorize with Brightcove
News | February 17, 2009

PET, PET/CT Studies Inched Up Just 4 Percent in 2008

February 17, 2009 - The total PET and PET/CT patient studies increased only 4 percent, from 1,457,400 to 1,520,800, compared to estimates for 2007 provided by respondents to a 2008 survey by IMV Medical Information Division, representing a slowdown in procedure growth.
Despite the 2008 figures represent a 35 percent increase over the same survey by IMV done in 2005, which estimated 1,129,900 patient studies were performed using PET or PET/CT, the recent slowdown may be caused by the Deficit Reduction Act (DRA) of 2005, indicated Lorna Young, senior director, Market Research at IMV.
“The estimated 1,520,800 clinical PET patient studies performed in 2008 represent a 35% increase over IMV’s 2005 estimate of 1,129,900 patient studies, for an average annual growth rate of 10.4 percent over the three-year period,” said Young. “With the advent of the Deficit Reduction Act (DRA) of 2005, related legislation against self-referral for standalone imaging centers, the increased scrutiny of third party insurers in their preauthorization processes and the reduction in the availability of capital, the market for PET purchases may continue to slow over the next few years.”
The report just released by IMV accounted for PET studies performed in 2,000 U.S. hospital and non-hospital sites, using fixed or mobile PET/CT or PET scanners.
Young added, “The PET market for fixed PET imaging units is still relatively early in its adoption cycle, as over half of the PET sites use a mobile service provider, while over 900 sites own one or more fixed PET or PET/CT scanners. A market forecast scenario presented in the report shows that over the next few years, 55 percent of the PET scanner demand will come from first buyers, who currently use mobile services, 30 percent will be replacement buyers and 15 percent will be additional buyers.”
The survey also noted that of the patient studies performed on PET or PET/CT scanners, 94 percent are for oncology applications, and 6 percent are for cardiology and neurology applications.

For more information: www.mvinfo.com

Related Content

FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
PET Imaging Agent Could Provide Early Diagnosis of Rheumatoid Arthritis

Coronal 18F-FEDAC PET/CT section of a mouse with collagen-induced arthritis. (A) On day 23 and day 37, increased uptake is noted in the front and hind paws of this mouse with collagen-induced arthritis. (B) Predictive performance of day 23 18F-FEDAC uptake for the development of clinical arthritis. ROC = receiver operating characteristic; Sn = sensitivity; Sp = specificity. Credit: Seoul National University and Ewha Womans University, Seoul, South Korea

News | PET Imaging | May 17, 2018
A novel positron emission tomography (PET) tracer developed by Korean researchers can visualize joint inflammation and...
PET Imaging Shows Protein Clumping May Contribute to Heart Failure Development
News | PET Imaging | May 11, 2018
A team led by Johns Hopkins University Researchers has discovered that protein clumps appear to accumulate in the...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
Novel PET Agent Could Help Guide Therapy for Brain Diseases

Rat brain 11C‐Me‐NB1 PET images (0‐60 min) superimposed on an MRI template. Credit: SD Krämer et al., ETH Zurich, Zurich, Switzerland

News | PET Imaging | April 10, 2018
Researchers have developed a new imaging agent that could help guide and assess treatments for people with various...
Imaging agent helps predict success of lung cancer therapy
News | Oncology Diagnostics | March 08, 2018
March 8, 2018 – Doctors contemplating the best therapy for...
In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows).

In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows). Image courtesy of A Piccardo et al., Galliera Hospital, Genoa, Italy.

News | Prostate Cancer | March 07, 2018
An Italian study featured in the March i
Overlay Init